Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-018 versus best available therapy in myelofibrosis with severe thrombocytopenia
2021-000369-34Phase 2Terminated
- Sponsor
- NS Pharma, Inc.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ilginatinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by NS Pharma, Inc. Primary endpoint: Proportion of subjects who achieve at least 35%. Started May 2022; status: terminated.
02
Drugs
ilginatinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2021-000369-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000369-34.